硼替佐米联合多柔比星脂质体治疗多发性骨髓瘤的临床观察

目的:观察硼替佐米联合多柔比星脂质体方案治疗多发性骨髓瘤（multiple myeloma，MM）的临床疗效和毒副反应。方法:MM患者69例，均给予硼替佐米联合多柔比星脂质体方案治疗6个疗程。结果:6疗程后69例患者中完全缓解（complete response，CR）为42.03%（29/69），总有效率为85.51%（59/69）。大于等于60岁患者和小于60岁患者临床疗效两组之间无显著性差异（P>0.05）。不同临床分型各组临床疗效之间无显著性差异（P>0.05）。治疗后血红蛋白较治疗前明显升高，骨髓浆细胞、血M蛋白明显降低，差异显著（P＜0.05）。毒副反应程度均可耐受。结论:硼替佐米联合多柔比星脂质体方案治疗MM完全缓解率及总有效率高，对不同分型及年龄组疗效均显著，值得进一步临床观察和推广。

Clinical observation of bortezomib combined with doxorubicin liposome in the treatment of multiple myeloma

Objective:To observe the clinical efficacy and side effects of bortezomib combined with doxorubicin liposome in the treatment of multiple myeloma.Methods:69 patients with multiple myeloma were treated with bortezomib combined with doxorubicin liposome for 6 courses.Results:After 6 courses of treatment,the complete response（CR） of 69 patients was 42.03%(29/69),and the total effective rate was 85.51%(59/69).There was no significant difference in the clinical efficacy between the patiets older than 60 years old group and those younger than 60 years old (P>0.05).After treatment,hemoglobin increased significantly higher than before treatment,and bone marrow plasma cells and blood M protein decreased significantly (P<0.05).The degree of adverse reaction can be tolerated.Conclusion:Bortezomib combined with doxorubicin liposome has high total remission rate and high total effective rate in the treatment of multiple myeloma.It has a significant effect on different types and age groups.It is worth further clinical observation and promotion.